Literature DB >> 16618544

Automated, high-resolution cellular retention and uptake studies in vitro.

Henrik Björke1, Karl Andersson.   

Abstract

This report describes an automated method for the measurements of cellular retention and uptake of radiolabeled proteins interacting with cell-surface receptors on intact cancer cells. A complete uptake and retention measurement was performed in one cell dish using a rotating radioimmunoassay (RIA) principle. Compared to common manual measurements, rotating RIA saved both labor time and reagents and provided real-time binding traces with superior time-resolution. The rotating RIA retention profiles for different interactions agreed with retention times reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618544     DOI: 10.1016/j.apradiso.2006.03.002

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  23 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.

Authors:  Hanna Björkelund; Lars Gedda; Magnus Malmqvist; Karl Andersson
Journal:  Mol Clin Oncol       Date:  2012-10-30

3.  (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.

Authors:  Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

4.  Evaluation of [18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS.

Authors:  Amanda J Weeks; Maite Jauregui-Osoro; Marcel Cleij; Julia E Blower; James R Ballinger; Philip J Blower
Journal:  Nucl Med Commun       Date:  2011-02       Impact factor: 1.690

5.  Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.

Authors:  Hanna Björkelund; Lars Gedda; Karl Andersson
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

6.  Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression.

Authors:  Gaurav Malviya; E F J de Vries; Rudi A Dierckx; Alberto Signore
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

7.  Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.

Authors:  Hanna Björkelund; Lars Gedda; Pavel Barta; Magnus Malmqvist; Karl Andersson
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

8.  CD14 mediates binding of high doses of LPS but is dispensable for TNF-α production.

Authors:  Kinga Borzęcka; Agnieszka Płóciennikowska; Hanna Björkelund; Andrzej Sobota; Katarzyna Kwiatkowska
Journal:  Mediators Inflamm       Date:  2013-12-30       Impact factor: 4.711

9.  Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods.

Authors:  Louise Dubois; Karl Andersson; Anna Asplund; Hanna Björkelund
Journal:  BMC Res Notes       Date:  2013-12-18

10.  Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain.

Authors:  Yongsheng Liu; Anzhelika Vorobyeva; Tianqi Xu; Anna Orlova; Annika Loftenius; Theresa Bengtsson; Per Jonasson; Vladimir Tolmachev; Fredrik Y Frejd
Journal:  Pharmaceutics       Date:  2021-06-07       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.